Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Holdings Trimmed by Maven Securities LTD

Maven Securities LTD lessened its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Rating) by 93.8% in the third quarter, HoldingsChannel reports. The fund owned 25,000 shares of the biopharmaceutical company’s stock after selling 375,000 shares during the period. Maven Securities LTD’s holdings in Cellectar Biosciences were worth $84,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. 1900 Wealth Management LLC acquired a new stake in Cellectar Biosciences in the third quarter worth about $40,000. State Street Corp raised its position in shares of Cellectar Biosciences by 4.5% during the 2nd quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 6,800 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cellectar Biosciences by 31.3% in the 2nd quarter. Renaissance Technologies LLC now owns 166,500 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 39,700 shares during the period. Finally, Worth Venture Partners LLC boosted its holdings in shares of Cellectar Biosciences by 122.8% in the first quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 252,570 shares in the last quarter. Institutional investors own 23.23% of the company’s stock.

Analysts Set New Price Targets

CLRB has been the topic of several recent analyst reports. StockNews.com assumed coverage on Cellectar Biosciences in a report on Monday. They set a “sell” rating on the stock. Maxim Group cut their price objective on Cellectar Biosciences to $7.00 in a report on Tuesday, November 15th.

Cellectar Biosciences Price Performance

NASDAQ CLRB opened at $1.58 on Wednesday. Cellectar Biosciences, Inc. has a 12 month low of $1.25 and a 12 month high of $7.90. The company has a market capitalization of $15.39 million, a P/E ratio of -0.39 and a beta of 1.17. The company’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $2.32.

About Cellectar Biosciences

(Get Rating)

Cellectar Biosciences, Inc engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.